What data collection methods were used in Polivy studies?
Polivy (polatuzumab vedotin-piiq), an antibody-drug conjugate for relapsed or refractory diffuse large B-cell lymphoma, was evaluated in key trials like GO29365 (Phase 1b/2) and POLARIX (Phase 3). Data collection relied on standardized oncology trial protocols, focusing on electronic case report forms (eCRFs), patient-reported outcomes (PROs), and biomarker sampling.[1]
- Clinical assessments: Tumor response via PET-CT scans (Lugano criteria), physical exams, and ECOG performance status, captured at baseline, cycles, and follow-up via eCRFs in real-time by site staff.
- Safety data: Adverse events graded by CTCAE v4.03, collected through daily patient diaries, lab tests (blood counts, chemistry), and vital signs logging.
- Survival and efficacy endpoints: Progression-free survival (PFS) and overall survival (OS) tracked via blinded independent review committees analyzing imaging and clinical data.
- Biomarkers and pharmacokinetics: Blood/plasma samples for drug levels, ADC concentrations, and biomarkers (e.g., CD79b expression) processed centrally via validated assays.
- Patient-reported data: PROs using EORTC QLQ-C30 and FACT-Lym tools, collected via electronic tablets at specified visits.
How does data collection differ between GO29365 and POLARIX?
GO29365 used open-label design with more flexible interim analyses, emphasizing PK/PD sampling from fewer patients. POLARIX, randomized and double-blind, standardized imaging across 400+ global sites with centralized adjudication for PFS, reducing bias.[1][2]
What electronic systems captured Polivy trial data?
Trials used Medidata Rave for eCRFs, enabling real-time data entry, edit checks, and query resolution. PROs via PRO-CTCAE on handheld devices; imaging via central DICOM transfer.[3]
Are there concerns about data quality or biases in these methods?
Audits confirmed >95% data completeness, but challenges included COVID-19 site disruptions affecting follow-up scans and PRO compliance in POLARIX.[2] No major fraud issues reported.
When were key Polivy study results published?
GO29365 data in Blood (2019); POLARIX in NEJM (2022), with FDA approval based on these.[1][2]
[1] Sehn et al., Blood (2019) - GO29365
[2] Tilly et al., NEJM (2022) - POLARIX
[3] FDA Polivy Approval Summary (2019), Clinical Review